JOHNS CREEK, Ga., Sept. 29, 2026 (GLOBE NEWSWIRE) — Saia, Inc. (Nasdaq: SAIA) announced that it will release its quarterly financial results before the market opens on Thursday, October 29th. Saia management will host a conference call to discuss the results later that morning at 10:00 a.m. Eastern Time.

To participate in the call, please dial 1-833-890-5317 and request to join the Saia, Inc. call. Callers should dial in five to ten minutes in advance of the conference call. This call will be webcast live via the company website at https://www.saia.com/about-us/investor-relations/financial-releases. A replay of the call will be offered two hours after the completion of the call through November 29, 2026 at 11:59 P.M. Eastern Time. The replay will be available by dialing 1-855-669-9658 referencing conference ID #3959947.

Saia, Inc. (Nasdaq: SAIA) offers customers a wide range of less-than-truckload, brokered truckload, expedited transportation and other logistics services. With headquarters in Georgia, Saia LTL Freight operates 218 terminals with national service. For more information on Saia, Inc. visit the Investor Relations section at https://www.saia.com/about-us/investor-relations.

CONTACT:      Saia, Inc.
    Matthew Batteh
    Executive Vice President and Chief Financial Officer
    Investors@Saia.com 

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) — Verizon Communications Inc. (NYSE, Nasdaq: VZ) today announced the election of Charles Phillips, Co-Founder & Managing Partner of Recognize Partners LP (“Recognize”), to the Verizon Board of Directors, effective immediately.

“Charles is an accomplished leader with distinctive experience in technology, financial and regulatory environments,” said Dan Schulman, Verizon CEO. “We look forward to his perspective and contributions on the board to help us innovate faster, delight our customers and drive sustainable, long-term value for our shareholders.”

With the addition of Mr. Phillips, the Verizon board consists of 10 directors with a broad mix of perspectives and expertise.

Mr. Phillips has served as Co-Founder and Managing Partner of Recognize, a private equity firm focused on investing in technology services businesses, since January 2020. Prior to Recognize, Mr. Phillips was the Executive Chairman of Infor, Inc., an enterprise software application provider, from 2019 to 2020 and Chief Executive Officer from 2010 to 2020. He served as President of Oracle Corporation from 2003 to 2010 and as a Managing Director in Morgan Stanley’s Technology Group from 1996 to 2003. Mr. Phillips also served as Captain in the U.S. Marine Corps.

Mr. Phillips holds a B.S. in Computer Science from the U.S. Air Force Academy, an M.B.A. from Hampton University and a J.D. from New York Law School. He also serves on the boards of directors of American Express, Bloomberg LP, Compass Inc., the Apollo Theater, and the Council of Foreign Relations.

This announcement was originally published by Verizon. Read the original press release.

Verizon Communications Inc. (NYSE, Nasdaq: VZ) powers and empowers how its millions of customers live, work and play, delivering on their demand for mobility, reliable network connectivity and security. Headquartered in New York City, serving countries worldwide and nearly all of the Fortune 500, Verizon generated revenues of $138.2 billion in 2025. Verizon’s world-class team never stops innovating to meet customers where they are today and equip them for the needs of tomorrow. For more, visit verizon.com or find a retail location at verizon.com/stores

Media contact: 
Katie Magnotta
201-602-9235
katie.magnotta@verizon.com

MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The meeting will be held Oct. 9-12, 2026, in Phoenix.

Barostim will be featured across eight events at HFSA, including late-breaking clinical data, a rapid-fire session, posters and podium sessions. BENEFIT-HF, the landmark clinical trial initiated earlier this year evaluating Barostim in an expanded population, will also be included in the clinical trial ePoster hub.

New REBALANCE Registry and Real-World HFmrEF Evidence
In a late-breaking session, Dr. Dmitry Yaranov will present new analyses from the REBALANCE Registry, the largest real-world study of Barostim-treated patients to date, evaluating the safety and benefits of Barostim in commercial use.

In a separate rapid-fire session, Dr. Javed Butler will present Baroreflex Activation Therapy in HFmrEF: First Real-World Evidence of Reduced Hospitalization Burden.

In addition to the REBALANCE and HFmrEF presentations, Barostim will be featured in numerous scientific sessions and activities throughout the HFSA Annual Scientific Meeting 2026.

Barostim on the HFSA Annual Scientific Meeting 2026 Agenda

Friday, Oct. 9:

  • Devices in Heart Failure Meeting, Discussion Forum – Making a Choice CCM or Barostim (Dr. Elizabeth Volz and Dr. Omar Cantu Martinez)
  • Devices in Heart Failure Meeting, Trial Tinder: Choose my Trial! – BENEFIT-HF (Dr. Farooq Sheikh)
  • ePoster, Barostim Enabled Neurohormonal Intervention for Improving Treatment of Heart Failure (BENEFIT-HF) (Dr. William Abraham)

Saturday, Oct. 10:

  • Poster, Interaction Testing Between Barostim Neo Device and Assure Wearable Cardiac Defibrillator (Dr. Rhea Verma)

Sunday, Oct. 11:

  • Sunday Plenary Session, The REBALANCE Registry: Real World Outcomes Following Baroreflex Activation Therapy (Dr. Dmitry Yaranov)
  • Rapid Fire Session 2, Baroreflex Activation Therapy in HFmrEF: First Real-World Evidence of Reduced Hospitalization Burden (Dr. Javed Butler)
  • Poster, Optimizing Management of Heart Failure with Reduced Ejection Fraction Using Baroreflex Activation Therapy: A Path to Diuretic Independence (Dr. Shreya Srivastava)

Monday, Oct. 12:

  • Game of Thrones House of Devices: Restoring the Realm’s Failing Hearts, House Lannister: Barostim Takes Up Arms (Dr. Sarah Chuzi)

CVRx Sponsored Programs
CVRx will host two symposia sharing insights on Barostim’s role in the heart failure care continuum and its integration into clinical practice.

On Friday, Oct. 9 from 7:00–8:30 a.m., Device-Based Neurohormonal Intervention: The Role of Barostim in Heart Failure Care will explore the clinical evidence supporting Barostim, patient selection, integration into guideline-directed care and practical considerations for implementation.

On Sunday, Oct. 11 from 1:00–2:00 p.m., Successful Barostim Program Development: A Critical Component of the Heart Failure Care Continuum will address multidisciplinary collaboration, patient identification, referral pathways, workflow integration and best practices for developing and sustaining a successful Barostim program.

“We are excited by the scientific interest in Barostim at this year’s HFSA conference, with four separate data sets, five podium discussions and two symposia focused on practical elements for incorporating Barostim into clinical practice,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “The data being presented provide important new scientific insights about Barostim across patient populations, clinical outcomes and real-world practice, contributing to a broader understanding of its role in the heart failure continuum.”

About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure.

Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com

Tokyo, JAPAN and New York, NY, Sept. 29, 2026 (GLOBE NEWSWIRE) — Linkage Global Inc. (NASDAQ: UZX) (“Linkage Global” or the “Company”), a technology-driven enterprise focused on AI-enabled wellness infrastructure, today announced that the non-binding term sheet dated September 12, 2026 between the Company and Capital Finance Limited (“Capital Finance”), as amended by an addendum dated September 14, 2026 (collectively, the “LOI”), relating to a proposed strategic equity investment of up to US$20 million, was terminated effective September 28, 2026.

On September 28, 2026, the Company delivered, and Capital Finance acknowledged and agreed to, a written termination notice terminating the LOI with immediate effect. The parties will not proceed with the proposed transaction. No definitive securities purchase agreement was entered into, and no securities were issued or funds received in connection with the proposed transaction.

Except for provisions that expressly survive termination, the LOI ceased to have further force or effect on September 28, 2026. The termination does not affect any rights or remedies accrued before that date, and the confidentiality obligations under the LOI will remain in effect for three years following termination.

Linkage Global remains focused on its core business operations and will continue to evaluate strategic and financing opportunities that it believes may advance the interests of the Company and its shareholders.

About Linkage Global Inc.

Linkage Global Inc. (NASDAQ: UZX) is a technology-driven enterprise pioneering global AI-enabled wellness infrastructure. Through its proprietary Human Resonance OS, the Company integrates self-developed neural acoustic algorithms, a portfolio of original wellness audio copyrights, and next-generation smart wearables to deliver data-driven, proactive wellness solutions to B2B and B2C markets worldwide. Founded on March 24, 2022, Linkage Global is headquartered in Tokyo, Japan. For more information, visit: https://linkagecc.com

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s plans, strategies and business development initiatives. There can be no assurance that any strategic initiative, partnership, offering launch, or other business plan described herein will be successfully executed or completed. This press release does not constitute guidance and should not be relied upon as indicative of future financial performance. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.

For investor and media inquiries, please contact:

Linkage Global Inc.
Investor Relations
Email: ir@linkagecc.com

Houston, TX, Sept. 29, 2026 (GLOBE NEWSWIRE) — CenterPoint Energy, Inc. (NYSE: CNP) has scheduled a conference call for Tuesday, October 27, 2026, at 7:00 a.m. Central time or 8:00 a.m. Eastern time, to discuss Third Quarter results. Earnings will be released on the same day before the market opens.

CenterPoint Energy will provide a live audio webcast of the conference call, which can be accessed at CenterPointEnergy.com. Click on “Events & Presentations” and the link, “CenterPoint Energy, Inc. Third Quarter 2026 Earnings Conference Call Webcast.” The webcast will be archived on the company’s website for at least one year.

CenterPoint Energy, Inc.

Third Quarter 2026 Earnings Conference Call

Tuesday, October 27, 2026

7:00 a.m. Central / 8:00 a.m. Eastern

About CenterPoint Energy

As the only investor owned electric and gas utility based in Texas, CenterPoint Energy, Inc. (NYSE: CNP) is an energy delivery company with electric transmission and distribution, power generation and natural gas distribution operations that serve more than 7 million metered customers in Indiana, Minnesota, Ohio and Texas. As of June 30, 2026, the company owned approximately $48.3 billion in assets. With approximately 8,800 employees, CenterPoint Energy and its predecessor companies have been in business for more than 150 years. For more information, visit CenterPointEnergy.com.

CONTACT: Ben Vallejo | (713) 207-5461 | Ben.vallejo@centerpointenergy.com

BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the “Offering”) of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase shares of common stock. Each share of common stock and each pre-funded warrant will be sold together with a common warrant to purchase one share of common stock.

The common warrants will become exercisable only upon approval by the Company’s stockholders of an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of common stock and the effectiveness of that amendment (the date of such effectiveness, the “Charter Amendment Effective Date”), and will expire upon the earlier of (i) the fifth anniversary of the Charter Amendment Effective Date and (ii) the 30th calendar day following the later (x) of the Charter Amendment Effective Date and (y) the Company’s public disclosure of overall survival data (the “OS Data Release Date”) from its ongoing Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), expected in the first half of 2027. All of the securities in the Offering are to be sold by Pyxis Oncology.

Leerink Partners, Guggenheim Securities and Wells Fargo Securities are acting as joint bookrunning managers for the proposed Offering. The proposed Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering.

Pyxis Oncology intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner™, its planned Phase 3 trial in 2L+ R/M HNSCC, and for working capital and general corporate purposes.

The common stock, common warrants and pre-funded warrants are being offered pursuant to a registration statement on Form S-3 (File No. 333-291801), which was previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”). The Offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A copy of the preliminary prospectus supplement relating to and describing the terms of the Offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, at (800) 645-3751 (option #5) or email a request to WFScustomerservice@wellsfargo.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the Offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Pyxis Oncology

Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release, including without limitation statements regarding the anticipated Offering, including its timing, size, terms and completion and the anticipated gross proceeds therefrom (including from any exercise of the common warrants); the Company’s ability to obtain stockholder approval of, and to effect, the amendment to its certificate of incorporation required for the common warrants to become exercisable, and the timing thereof; the timing of the OS Data Release Date, which will affect the period during which the common warrants may be exercised; the Company’s intended use of the net proceeds from the Offering; the Company’s plans to develop, manufacture and commercialize MICVO; the timing and progress of the Company’s ongoing clinical trials and the expected results thereof; the plans and objectives of management; and the future results of operations and financial position of the Company, are forward-looking statements. These statements are neither promises nor guarantees, but are statements that involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: market and other conditions and the Company’s ability to complete the Offering on the anticipated terms, or at all; the Company’s ability to obtain the stockholder approval required for the common warrants to become exercisable; the timing and results of the overall survival analysis from the Company’s Phase 1 monotherapy study of MICVO; the risks inherent in drug research and development; the Company’s projected cash runway and potential needs for additional funding; the lengthy, expensive and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; the Company’s reliance on third parties and collaborators to conduct clinical trials, manufacture its product candidate, and develop and commercialize its product candidate; the Company’s ability to compete successfully against other drug candidates; and volatility in the price of the Company’s common stock. Accordingly, investors should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Additionally, investors should read the risk factors in the section titled “Risk Factors” set forth in Part II, Item 1A of the Company’s Quarterly Report on Form 10-Q filed on August 13, 2026, in the preliminary prospectus supplement relating to the Offering, and in the Company’s other filings, each of which is on file with the Securities and Exchange Commission.

Pyxis Oncology Contact:
IR@pyxisoncology.com

HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — Plains All American Pipeline, L.P. (Nasdaq: PAA) and Plains GP Holdings (Nasdaq: PAGP) (collectively, “Plains”) announced that Dean Liollio has been appointed to serve as Executive Vice President and Chief Operating Officer of Plains effective as of October 2, 2026. Mr. Liollio replaces Chris Chandler, the current EVP and COO, who is resigning from Plains to pursue other interests and not due to any disagreement relating to the company’s operations, policies or practices.

Mr. Liollio, age 67, served as Senior Vice President, Special Projects, of Plains from June 2024 until his appointment as EVP and COO in October 2026. He previously served as President of Plains Midstream Canada from 2020 until 2024, as President of PAA Natural Gas Storage from 2008 until 2020 and as President of Plains Gas Solutions from 2016 until 2020. Prior to joining Plains in 2008, Mr. Liollio held a number of executive roles including serving as President, Chief Executive Officer and Director of EnergySouth, Inc. and as President and Chief Operating Officer of Centerpoint’s natural gas distribution operations across a five-state area including Houston. Mr. Liollio holds a Bachelor of Science degree in Industrial Engineering from Texas A&M University.

“We congratulate Dean on his promotion to the EVP and COO role. Dean is immensely qualified to take on this key leadership role as he has been a member of our executive committee and has been instrumental in executing on our recent initiatives,” said Willie Chiang, Chairman, CEO and President. “I would also like to thank Chris for his many contributions to Plains and wish him the best in his future endeavors.”

About Plains
PAA is a publicly traded master limited partnership that owns and operates midstream energy infrastructure and provides logistics services for crude oil. PAA owns an extensive network of pipeline gathering and transportation systems, in addition to terminaling, storage, and other infrastructure assets serving key producing basins, transportation corridors and major market hubs and export outlets in the United States and Canada.

PAGP is a publicly traded entity that owns an indirect, non-economic controlling general partner interest in PAA and an indirect limited partner interest in PAA, one of the largest energy infrastructure and logistics companies in North America. 

PAA and PAGP are headquartered in Houston, Texas. More information is available at www.plains.com.

Investor Relations Contacts:
Blake Fernandez
Ross Hovde
PlainsIR@plains.com
(866) 809-1291

RENO, Nev., Sept. 29, 2026 (GLOBE NEWSWIRE) — Employers Holdings, Inc. (the “Company”) (NYSE:EIG) will release its third quarter 2026 financial results after market close on Wednesday, October 28, 2026, after which these materials will be available on the Company’s website at www.employers.com through the “Investors” link.

Conference Call Details
The Company will review these financial results via a conference call and webcast on Thursday, October 29, 2026, at 11:00 a.m. ET / 8:00 a.m. PT.

To participate in the live conference call, you must register here. Once registered you will receive a dial-in number and a unique PIN number. The webcast will be accessible on the Company’s website at www.employers.com through the “Investors” link.

An archived version of the webcast will be accessible on the Company’s website following the live call.

About EMPLOYERS
Employers Holdings, Inc. (NYSE: EIG), is a holding company with subsidiaries that are specialty providers of workers’ compensation insurance, excess workers’ compensation, and related services (collectively “EMPLOYERS®”) focused on small and mid-sized businesses engaged in lower hazard industries with its guaranteed cost product and self-insured enterprises with its excess workers’ compensation product. EMPLOYERS leverages over a century of experience to deliver comprehensive coverage solutions that meet the unique needs of its customers. Drawing from its long history and extensive knowledge, EMPLOYERS empowers businesses by protecting their most valuable asset – their employees – through exceptional claims management, loss control, and risk management services, to help businesses create safer work environments.

EMPLOYERS is also proud to offer Cerity®, which is focused on providing digital-first, direct-to-consumer workers’ compensation insurance solutions with fast and affordable coverage options through a user-friendly online platform.

EMPLOYERS operates throughout the United States, apart from four states that are served exclusively by their state funds. Workers’ Compensation insurance is offered through Employers Insurance Company of Nevada, Employers Compensation Insurance Company, Employers Preferred Insurance Company, Employers Assurance Company, and Cerity Insurance Company, and Excess Workers’ Compensation is offered through Employers Assurance Company. Each of EMPLOYERS insurance subsidiaries is rated A (Excellent) by AM Best. Not all companies do business in all jurisdictions. EIG Services, Inc., and Cerity Services, Inc., are subsidiaries of Employers Holdings, Inc. EMPLOYERS® is a registered trademark of EIG Services, Inc., and Cerity® is a registered trademark of Cerity Services, Inc. For more information, please visit www.employers.com, www.employers.com/excess-workers-compensation/, and www.cerity.com.

Contact Information
Michael Pedraja (775) 327-2706 or mpedraja@employers.com

MIAMI, Sept. 29, 2026 (GLOBE NEWSWIRE) — Laureate Education, Inc. (NASDAQ: LAUR) plans to release results for the quarter ended September 30, 2026, on Thursday, October 29, 2026, before the stock market opens. Following the release, the Company will host a conference call with investors and analysts at 8:30 a.m. ET to discuss the third quarter results and the Company’s business outlook.

Interested parties are invited to listen to the earnings conference call by registering here to receive dial in information.

The webcast of the conference call, including replays, and a copy of the earnings release and the related slides will be made available through the Investor Relations section of the Company’s website at www.laureate.net.

About Laureate Education, Inc.

Laureate Education, Inc. operates five higher education institutions across Mexico and Peru, enrolling approximately 500,000 students in high-quality undergraduate, graduate, and specialized degree programs through campus-based and online learning. Our universities have a deep commitment to academic quality and innovation, strive for market-leading employability outcomes, and work to make higher education more accessible. At Laureate, we know that when our students succeed, countries prosper, and societies benefit.

Investor Relations Contact:
ir@laureate.net

Media Contacts:
Laureate Education, Inc.
Adam Smith
adam.smith@laureate.net
U.S.: +1 (443) 255 0724

MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) — Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), a leading cannabis company and agricultural markets platform, today announced that it has entered into a Put/Call Agreement (the “Put/Call Agreement”) with Battle Green Holdings SR LLC (the “Note Holder”), pursuant to which the Note Holder may cause Vireo to acquire, or Vireo may elect to acquire, a loan issued pursuant to a promissory note (the “Note”) issued by BG Ohio SPV LLC to the Note Holder.

Pursuant to the terms of the Put/Call Agreement, the Note Holder will have the right, but not the obligation, to cause Vireo to acquire the Note (the “Put Right”) and Vireo will have the right, but not the obligation, to purchase the Note (the “Call Right”), in each case by issuing Vireo subordinate voting shares (“Vireo Shares”) at a price of US$19.50 per Vireo Share in the case of the Put Right or US$18.60 per Vireo Share in the case of the Call Right. In addition, at the maturity date of the Note, if neither the Put Right nor the Call Right has been exercised, Vireo will acquire the Note by issuing Vireo Shares at the trailing 30-day volume weighted average price of the Vireo Shares (the “Maturity Call Right”). Additional Vireo Shares may be issuable in respect of accrued interest on the Note, subject to Vireo’s right to pay such interest in cash. The Put/Call Agreement has a term of three years. If the Put Right or Call Right is exercised, Vireo would issue a maximum of 972,905 Vireo Shares, based on a principal amount under the Note of US$18,096,028. If the Maturity Call Right is exercised, the number of Vireo Shares issuable will be determined based on the trailing 30-day volume weighted average price at the time of exercise, subject to applicable CSE pricing minimums. No Vireo Shares will be issued unless and until the Put Right, Call Right, or Maturity Call Right is exercised and all applicable conditions have been satisfied.

About Vireo Growth Inc.

Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) is a leading vertically integrated cannabis company building a broad platform across cannabis and adjacent agricultural markets. The Company operates cultivation, manufacturing, retail dispensaries, home delivery, distribution, and agricultural supply businesses across the United States, creating exposure to both cannabis and complementary adjacent markets. With operations in 10 states and more than 170 dispensaries nationwide, Vireo combines disciplined capital allocation, strategic acquisitions, and local market execution to scale its platform and drive long-term shareholder value. The Company is focused on expanding market share and strengthening its portfolio of consumer brands and services, while supporting the customers, employees, shareholders, and communities it serves. For more information about Vireo, visit www.vireogrowth.com.

Forward-Looking Information

This press release contains “forward-looking information” or “forward-looking statements” within the meaning of applicable United States and Canadian securities legislation (referred to herein as “forward-looking information”). Forward-looking information contained in this press release may be identified by the use of words such as “should,” “believe,” “estimate,” “would,” “looking forward,” “may,” “continue,” “expect,” “expected,” “will,” “likely,” “subject to,” and variations of such words and phrases, or any statements or clauses containing verbs in any future tense. Forward-looking information in this press release includes, without limitation, whether the Put Right, Call Right or Maturity Call Right will be exercised; the potential acquisition of the Note and the issuance of Vireo Shares pursuant to the Put/Call Agreement; the potential issuance amount and timing of any Vireo Shares pursuant to the Put/Call Agreement; and the potential impact of the Put/Call Agreement on the trading price of the Vireo Shares. These statements should not be read as guarantees of future performance or results.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: the potential dilutive impact and overhang resulting from the possible issuance of Vireo Shares in connection with the Put/Call Agreement; the Company’s ability to maintain relationships with suppliers, customers, employees and other third parties; the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions; risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to meet the demand for flower in its various markets; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on EDGAR with the U.S. Securities and Exchange Commission at www.sec.gov and filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.com.

The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

For Vireo, contact:
Lynn Ricci
Director Investor Relations & Corporate Communications
investor@vireogrowth.com
781-956-7052

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.